Abstract | OBJECTIVE: MATERIAL AND METHOD: All patients with delirium were assessed. The diagnosis of delirium was confirmed by using the Confusion Assessment Method (CAM). Quetiapine at the dose between 25 and 100 mg/day was given for 7 days. The efficacy of quetiapine on delirium was evaluated by using the Delirium Rating Scale (DRS) and the Clinical Global Impression-Severity scale (CGI-S). The extrapyramidal side effects were assessed by using the Modified (9-item) Simpson-Angus Scale (MSAS). RESULTS: Twenty-two patients had delirium. Seventeen (10 males and 7 females) subjects with a mean age (SD) of 55.6 (18.6) years were included in the present study. Means (SDs) dose and duration (SD) of quetiapine treatment were 45.7 (28.7) mg/day and 6.5 (2.0) days, respectively. The DRS and CGI-S scores of days 2-7 were significantly lower than those of day 0 (p < 0. 001) for all comparisons). Only two subjects were shown to have mild tremor. CONCLUSION:
Quetiapine within the range of 25-100 mg/day improves delirious condition within 24 hours of treatment. It is well-tolerated and has a very low propensity to induce extrapyramidal side effects. Further randomized, placebo-controlled trials are warranted.
|
Authors | Benchalak Maneeton, Narong Maneeton, Manit Srisurapanont |
Journal | Journal of the Medical Association of Thailand = Chotmaihet thangphaet
(J Med Assoc Thai)
Vol. 90
Issue 10
Pg. 2158-63
(Oct 2007)
ISSN: 0125-2208 [Print] Thailand |
PMID | 18041437
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Dibenzothiazepines
- Quetiapine Fumarate
|
Topics |
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Basal Ganglia Diseases
- Delirium
(drug therapy, physiopathology)
- Dibenzothiazepines
(adverse effects, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Neuropsychological Tests
- Prospective Studies
- Psychological Tests
- Psychometrics
- Quetiapine Fumarate
- Treatment Outcome
|